JP6787792B2 - がんの処置のための併用治療 - Google Patents

がんの処置のための併用治療 Download PDF

Info

Publication number
JP6787792B2
JP6787792B2 JP2016568918A JP2016568918A JP6787792B2 JP 6787792 B2 JP6787792 B2 JP 6787792B2 JP 2016568918 A JP2016568918 A JP 2016568918A JP 2016568918 A JP2016568918 A JP 2016568918A JP 6787792 B2 JP6787792 B2 JP 6787792B2
Authority
JP
Japan
Prior art keywords
cancer
antagonist
treatment
radiation
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016568918A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017516775A5 (enExample
JP2017516775A (ja
Inventor
バオ，シンフォン
アルブ，ダイアナ
ウッダール−ヤッペ，メアリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2017516775A publication Critical patent/JP2017516775A/ja
Publication of JP2017516775A5 publication Critical patent/JP2017516775A5/ja
Priority to JP2020096807A priority Critical patent/JP7562296B2/ja
Application granted granted Critical
Publication of JP6787792B2 publication Critical patent/JP6787792B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016568918A 2014-05-23 2015-05-21 がんの処置のための併用治療 Active JP6787792B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020096807A JP7562296B2 (ja) 2014-05-23 2020-06-03 がんの処置のための併用治療

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462002366P 2014-05-23 2014-05-23
US62/002,366 2014-05-23
US201562150004P 2015-04-20 2015-04-20
US62/150,004 2015-04-20
PCT/US2015/031931 WO2015179615A1 (en) 2014-05-23 2015-05-21 Combination therapies for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020096807A Division JP7562296B2 (ja) 2014-05-23 2020-06-03 がんの処置のための併用治療

Publications (3)

Publication Number Publication Date
JP2017516775A JP2017516775A (ja) 2017-06-22
JP2017516775A5 JP2017516775A5 (enExample) 2018-06-28
JP6787792B2 true JP6787792B2 (ja) 2020-11-18

Family

ID=53277114

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016568918A Active JP6787792B2 (ja) 2014-05-23 2015-05-21 がんの処置のための併用治療
JP2020096807A Active JP7562296B2 (ja) 2014-05-23 2020-06-03 がんの処置のための併用治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020096807A Active JP7562296B2 (ja) 2014-05-23 2020-06-03 がんの処置のための併用治療

Country Status (13)

Country Link
US (2) US20170182003A1 (enExample)
EP (2) EP3134085B1 (enExample)
JP (2) JP6787792B2 (enExample)
KR (1) KR102535283B1 (enExample)
CN (2) CN110354266A (enExample)
AU (1) AU2015264102C1 (enExample)
CA (1) CA2949961C (enExample)
IL (1) IL249065A0 (enExample)
MA (1) MA39906A (enExample)
MX (1) MX393818B (enExample)
RU (1) RU2708374C2 (enExample)
SG (1) SG11201609770TA (enExample)
WO (1) WO2015179615A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020128432A (ja) * 2014-05-23 2020-08-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 がんの処置のための併用治療

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3002144C (en) 2015-10-16 2024-01-23 Eisai R&D Management Co., Ltd. Ep4 antagonists
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
MX385428B (es) * 2016-07-07 2025-03-04 Ono Pharmaceutical Co Combinación que comprende antagonista del receptor 4 de prostaglandina e2 (ep4) e inhibidor de punto de control inmunitario.
EP3505183B1 (en) 2016-08-26 2022-03-30 Tetsuji Okuno Microvascular blood flow decreasing agent and use thereof
KR20230010826A (ko) 2016-10-14 2023-01-19 프리시젼 바이오사이언시스 인코포레이티드 B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제
US10342785B2 (en) * 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
AR111808A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
EA201992676A1 (ru) 2017-05-18 2020-05-06 Идорсия Фармасьютиклз Лтд Фенильные производные в качестве модуляторов pge2 рецепторов
KR102612140B1 (ko) 2017-05-18 2023-12-08 이도르시아 파마슈티컬스 리미티드 피리미딘 유도체
US11325899B2 (en) 2017-05-18 2022-05-10 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
PE20191787A1 (es) 2017-05-18 2019-12-24 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituidos
CN108929281B (zh) * 2017-05-27 2021-12-24 华东师范大学 三氮唑类化合物及其合成方法和应用
JP7159007B2 (ja) * 2017-11-01 2022-10-24 小野薬品工業株式会社 脳腫瘍の治療のための医薬
JP7037667B2 (ja) 2017-12-20 2022-03-16 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する３’３’環状ジヌクレオチド
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
US20200352906A1 (en) * 2018-02-05 2020-11-12 Shenzhen Ionova Life Science Co., Ltd. Heterobicyclic Carboxylic Acids for Treating Cancer or Inflammatory Diseases
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ， インコーポレイテッド Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
CN112292128A (zh) * 2018-04-16 2021-01-29 阿瑞斯医疗有限公司 Ep4抑制剂和其用途
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
US20210315909A1 (en) 2018-07-11 2021-10-14 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
WO2020081979A1 (en) * 2018-10-19 2020-04-23 Memorial Sloan-Kettering Cancer Center Low dose radiation conditioning for immunotherapy
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
KR102861190B1 (ko) 2019-01-22 2025-09-17 키테라 (쑤저우) 바이오-파마슈티컬스 컴퍼니 리미티드 Pge2/ep4 신호 전달을 억제하기 위한 화합물, 이의 제조 방법, 및 이의 의약적 용도
WO2020178769A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
CN113574063B (zh) 2019-03-07 2025-03-18 捷克共和国有机化学与生物化学研究所 3’3’-环二核苷酸及其前药
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
US20220233694A1 (en) * 2019-05-31 2022-07-28 The Cleveland Clinic Foundation Functionalized fullerene gel tumor treatment
CN110386941A (zh) * 2019-08-15 2019-10-29 上海邦耀生物科技有限公司 Ep4受体拮抗剂和pd-1抑制剂联合用于癌症的治疗
US20220296619A1 (en) 2019-08-19 2022-09-22 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
HRP20241379T1 (hr) 2019-09-30 2024-12-20 Gilead Sciences, Inc. Cjepiva za hbv i postupci za liječenje hbv
WO2021098750A1 (en) * 2019-11-21 2021-05-27 Beigene (Beijing) Co., Ltd. Methods of cancer treatment with anti-ox40 antibody in comibinaiton with tlr agonists
US12410418B2 (en) 2019-12-06 2025-09-09 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
IL296007B2 (en) * 2020-03-04 2026-03-01 Wuhan Humanwell Innovative Drug Res And Development Center Limited Company Synthesis of a novel EP4 antibody and use for cancer and inflammation
KR102987126B1 (ko) 2020-03-20 2026-07-07 길리애드 사이언시즈, 인코포레이티드 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법
WO2022037601A1 (zh) * 2020-08-18 2022-02-24 武汉人福创新药物研发中心有限公司 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在制备治疗癌症和炎症药物中的用途
TWI877433B (zh) * 2020-11-30 2025-03-21 大陸商杭州阿諾生物醫藥科技有限公司 用於治療ｐｉｋ３ｃａ突變癌症的組合療法
TWI916497B (zh) 2021-01-28 2026-03-01 大陸商深圳眾格生物科技有限公司 咪唑醯胺衍生物及其藥物組合物、製備方法和應用
US20240269142A1 (en) 2021-05-13 2024-08-15 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
JP7900421B2 (ja) 2021-06-11 2026-08-04 ギリアード サイエンシーズ， インコーポレイテッド Ｍｃｌ－１阻害剤と抗がん剤との組み合わせ
TWI861509B (zh) 2021-06-11 2024-11-11 美商基利科學股份有限公司 Mcl-1抑制劑與抗體藥物接合物之組合
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
CA3230557A1 (en) * 2021-09-03 2023-03-09 Xuejun Zhang Ep4 antagonist compound as well as salt, polymorph, and use thereof
CN115364222A (zh) * 2021-09-09 2022-11-22 首都医科大学附属北京地坛医院 Ep4受体抑制剂治疗肝纤维化的应用
US20250381143A1 (en) * 2021-12-30 2025-12-18 Adlai Nortye Biopharma Co., Ltd. A solid pharmaceutical composition
WO2024027599A1 (zh) * 2022-08-04 2024-02-08 杭州阿诺生物医药科技有限公司 预测直肠癌对an0025联合放疗/放化疗(rt/crt)治疗敏感性的生物标志物
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
TW202608468A (zh) 2024-05-13 2026-03-01 美商基利科學股份有限公司 組合療法
US20250345390A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
ZA200604579B (en) * 2003-12-08 2007-10-31 Univ Arizona Synergistic anti-cancer compositions
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
AU2007283404B2 (en) * 2006-08-11 2013-04-18 Merck Canada Inc. Thiophenecarboxamide derivatives as EP4 receptor ligands
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
JP5411927B2 (ja) 2008-05-06 2014-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１アンタゴニストとしてのピラゾール化合物
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
CA2754702C (en) * 2009-04-22 2016-06-07 Yukinori Take Selective ep4 antagonistic substance for treatment of cancer
WO2011041613A2 (en) 2009-09-30 2011-04-07 Memorial Sloan-Kettering Cancer Center Combination immunotherapy for the treatment of cancer
WO2012039972A1 (en) * 2010-09-21 2012-03-29 Eisai R&D Management Co., Ltd. Pharmaceutical composition
WO2013090552A1 (en) * 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
SG11201609770TA (en) * 2014-05-23 2016-12-29 Eisai R&D Man Co Ltd Combination therapies for the treatment of cancer

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020128432A (ja) * 2014-05-23 2020-08-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 がんの処置のための併用治療
JP7562296B2 (ja) 2014-05-23 2024-10-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 がんの処置のための併用治療

Also Published As

Publication number Publication date
MA39906A (fr) 2017-03-01
JP2017516775A (ja) 2017-06-22
MX393818B (es) 2025-03-24
RU2708374C2 (ru) 2019-12-06
EP3134085B1 (en) 2025-07-02
RU2016150650A (ru) 2018-06-26
US20220071959A1 (en) 2022-03-10
AU2015264102C1 (en) 2020-10-08
JP7562296B2 (ja) 2024-10-07
US20170182003A1 (en) 2017-06-29
WO2015179615A1 (en) 2015-11-26
KR20170017933A (ko) 2017-02-15
EP4656246A2 (en) 2025-12-03
CN110354266A (zh) 2019-10-22
KR102535283B1 (ko) 2023-05-22
RU2016150650A3 (enExample) 2018-12-25
SG11201609770TA (en) 2016-12-29
CA2949961A1 (en) 2015-11-26
AU2015264102B2 (en) 2020-02-13
IL249065A0 (en) 2017-01-31
JP2020128432A (ja) 2020-08-27
CA2949961C (en) 2023-09-19
AU2015264102A1 (en) 2016-12-08
EP3134085A1 (en) 2017-03-01
EP4656246A3 (en) 2026-01-14
CN106572993A (zh) 2017-04-19
CN106572993B (zh) 2019-07-16
US11707448B2 (en) 2023-07-25
MX2016015363A (es) 2017-05-30

Similar Documents

Publication Publication Date Title
JP7562296B2 (ja) がんの処置のための併用治療
JP7190549B2 (ja) Ｈｄａｃ阻害剤とｐｄ－１阻害剤との組み合わせ療法
JP7190548B2 (ja) Ｈｄａｃ阻害剤とｐｄ－ｌ１阻害剤との組み合わせ療法
JP7578643B2 (ja) 異常な細胞成長を処置するための方法および組成物
TWI786044B (zh) 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
US8435992B2 (en) Multiple myeloma treatments
WO2014142220A1 (ja) 抗腫瘍剤
JP7547360B2 (ja) Ｐｋｍ２モジュレーターを含む組成物およびそれを使用する処置の方法
WO2021129616A1 (zh) 抗pd-1抗体和组蛋白去乙酰化酶抑制剂的药物组合及其用途、使用方法
TW201306833A (zh) 包含康布列塔司他汀（ｃｏｍｂｒｅｔａｓｔａｔｉｎｓ）族衍生物及西妥昔單抗（ｃｅｔｕｘｉｍａｂ）之組合
BR112016027512B1 (pt) Usos combinados de um antagonista de ep4 no tratamento de câncer e geração de uma resposta imune de memória contra um câncer
Khalid et al. Desensitization of brentuximab vedotin in a patient with Hodgkin lymphoma
HK40129132A (en) Combination therapies of hdac inhibitors and pd-1 inhibitors
NZ788180A (en) Combination therapy with notch and pd-1 or pd-l1 inhibitors
JP2016104704A (ja) 抗腫瘍剤
TW201313225A (zh) 與放射線治療關聯之包含奧瑞布林（ｏｍｂｒａｂｕｌｉｎ）及順鉑（ｃｉｓｐｌａｔｉｎ）之抗腫瘤組合

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190515

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190917

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200709

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200806

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200923

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201029

R150 Certificate of patent or registration of utility model

Ref document number: 6787792

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250